^
Association details:
| Biomarker: | CD33 expression + CD7 expression |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | BVX001 (Microtubule inhibitor, CD33-targeted antibody-drug conjugate, CD7-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract 2887: Bispecific antibody drug conjugates targeting CD7 and CD33 for the treatment of acute myeloid leukemia
Published date:
06/23/2020
Excerpt:
BVX100-vcMMAE had 5-fold lower cytotoxicity towards Jurkat cells (CD7+CD33-) and >10-fold margins relative to MV4.11 and SHI-1 (CD7-CD33+) cells whereas corresponding homo-dimeric Bi-Fabs were non-selective….Anti-CD7, anti-CD33 Bi-Fab drug conjugates are highly cytotoxic to CD7+CD33+ cells in vitro and in vivo, and have substantially greater selectivity than monospecific drug conjugates for such cells, supporting the development of bispecific antibody drug conjugates targeting CD7 and CD33 for the treatment of CD7+/CD33+ AML.
DOI:
10.1158/1538-7445.AM2020-2887
